Clinicopathological studies suggest that Alzheimer's disease (AD) pathology begins ~10–15 years before the resulting cognitive impairment draws medical attention. Biomarkers that can detect AD pathology in its early stages and predict dementia onset would, therefore, be invaluable for patient care and efficient clinical trial design. We utilized a targeted proteomics approach to discover novel cerebrospinal fluid (CSF) biomarkers that can augment the diagnostic and prognostic accuracy of current leading CSF biomarkers (Aβ42, tau, p-tau181).
Methods and Findings
Using a multiplexed Luminex platform, 190 analytes were measured in 333 CSF samples from cognitively normal (Clinical Dementia Rating [CDR] 0), very mildly demented (CDR 0.5), and mildly demented (CDR 1) individuals. Mean levels of 37 analytes (12 after Bonferroni correction) were found to differ between CDR 0 and CDR>0 groups. Receiver-operating characteristic curve analyses revealed that small combinations of a subset of these markers (cystatin C, VEGF, TRAIL-R3, PAI-1, PP, NT-proBNP, MMP-10, MIF, GRO-α, fibrinogen, FAS, eotaxin-3) enhanced the ability of the best-performing established CSF biomarker, the tau/Aβ42 ratio, to discriminate CDR>0 from CDR 0 individuals. Multiple machine learning algorithms likewise showed that the novel biomarker panels improved the diagnostic performance of the current leading biomarkers. Importantly, most of the markers that best discriminated CDR 0 from CDR>0 individuals in the more targeted ROC analyses were also identified as top predictors in the machine learning models, reconfirming their potential as biomarkers for early-stage AD. Cox proportional hazards models demonstrated that an optimal panel of markers for predicting risk of developing cognitive impairment (CDR 0 to CDR>0 conversion) consisted of calbindin, Aβ42, and age.
Using a targeted proteomic screen, we identified novel candidate biomarkers that complement the best current CSF biomarkers for distinguishing very mildly/mildly demented from cognitively normal individuals. Additionally, we identified a novel biomarker (calbindin) with significant prognostic potential.
Citation: Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, et al. (2011) Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis. PLoS ONE 6(4): e18850. doi:10.1371/journal.pone.0018850
Editor: Ashley I. Bush, Mental Health Research Institute of Victoria, Australia
Received: November 28, 2010; Accepted: March 21, 2011; Published: April 19, 2011
Copyright: © 2011 Craig-Schapiro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant to Washington University from Pfizer. Max Kuhn, Eve H. Pickering, Thomas P. Misko, Kelly R. Bales and Holly Soares are employed by Pfizer Global Research and Development, Groton, CT, and St. Louis, MO and therefore, Pfizer Global played a role in study design, data collection and analysis, decision to publish, and preparation of the manuscript. This work was also supported by the National Institutes of Health grants P50 AG05681, P01 AG03991, P01 AG026276, P30 NS057105 and the Charles and Joanne Knight Alzheimer Research Initiative. This publication was made possible by Grant Number UL1 RR024992 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research. Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH. In regard to the funders other than Pfizer, they had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have read the journal's policy and have the following conflicts: Max Kuhn, Eve H. Pickering, Kelly R. Bales are paid employees of Pfizer. They have no other competing interests relevant to the data in this manuscript. Thomas P. Misko and Holly Soares were paid employees of Pfizer during the course of this study. They have no other competing interests relevant to the data in this manuscript. David M. Holtzman co-founded the company C2N Diagnostics and has ownership interests. He serves on the Scientific Advisory Boards of En Vivo and Satori. He has no other competing interests relevant to the data in this manuscript. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. Rebecca Craig-Schapiro, Chengjie Xiong, Jingxia Liu, Richard J. Perrin, and Anne M. Fagan have no competing interests to declare.
With the growing prevalence of Alzheimer's disease (AD), the ability to accurately and reliably diagnose AD in its earliest stages has become a public health priority. The concept of ‘earliest stages,’ however, warrants revision as it is increasingly clear there exists a ‘preclinical’ or ‘presymptomatic’ stage during which the pathological changes associated with AD, amyloid plaques, neurofibrillary tangles, and neuroinflammation, begin to appear without concomitant clinical features. This period has been estimated to be ~10–15 years in duration. Means to identify this preclinical phase of AD may facilitate medical intervention to prevent or slow neurodegeneration and the resulting cognitive impairment. Because clinical examination cannot detect preclinical disease and is less accurate with very mild stages of AD, there is a pressing need for biomarkers for AD. Furthermore, biomarkers may have significant utility in clinical trial design, providing greater diagnostic certainty for enrollment than is possible by clinical diagnosis alone, and allowing for the selective enrollment of individuals at greater risk of developing future cognitive impairment, ultimately resulting in trials of shorter duration, smaller size, and reduced cost.
The cerebrospinal fluid (CSF) is a logical source of potential AD biomarkers, as it reflects biochemical changes in the brain. Indeed, the fluid biomarkers thus far showing the greatest promise for use in AD diagnosis and prognosis are CSF amyloid-β42 (Aβ42), tau, and phosphorylated forms of tau (p-tau) ]–[. Concentrations of CSF Aβ42 decrease in association with the deposition of Aβ42 into plaques within the brain ]–[. This process occurs years prior to the clinical onset of AD and may mark the earliest phase of AD pathology. CSF Aβ42 levels remain low throughout the disease course , , . In contrast, CSF tau and p-tau levels progressively increase with the advancing stages of AD, and in some individuals, begin to rise several years prior to diagnosis , , . The ratios of tau or p-tau to Aβ42 have also proven useful for predicting clinical progression in individuals who have very mild dementia or mild cognitive impairment (MCI), and, importantly, for predicting future MCI and AD dementia among those who are cognitively normal , , . Nevertheless, even for these analytes, there is substantial overlap between control and AD groups and a need for better prognostic ability . Consequently, there remains a need for supplemental biomarkers to improve diagnosis and prognosis at different disease stages. Given the multifactorial nature of AD pathophysiology, it is likely that there will be other CSF biomarkers that will be useful in this regard. While proteomic screens have identified a number of other candidate AD biomarkers ]–[, few studies have utilized large, well-characterized cohorts or have looked for biomarkers in preclinical or very early stage disease.
In this study, a large number of CSF samples (N = 333) selected from well-characterized MCI/very early stage-AD and cognitively normal control cohorts were chosen for protein profiling using a commercially available panel that measures a variety of cytokines, chemokines, metabolic markers, growth factors, and other markers. Multiplex immunoassay platforms such as the one used here, Rules Based Medicine Discovery MAP 1.0 panel, allow for the simultaneous quantitation of many analytes, and by adhering to clinical laboratory improvement amendments (CLIA) standards, are amenable for clinical trial work. Using multiple statistical approaches, we have identified a set of novel biomarkers that may improve the ability of traditional AD biomarkers, Aβ42 and tau, to distinguish MCI/early-stage AD from cognitive normalcy and to predict the development of future cognitive impairment (i.e. detection of preclinical AD at increased risk of progression).
The study protocols were approved by the Human Studies Committees at all participating institutions, and written and verbal informed consent was obtained from participants at enrollment. All aspects of this study were conducted according to the principles expressed in the Declaration of Helsinki.
Participants (N = 333) were community-dwelling volunteers enrolled in longitudinal studies of healthy aging and dementia at the Knight Alzheimer's Disease Research Center at Washington University (WU-ADRC). The study protocol was approved by the Human Studies Committee at Washington University, and written and verbal informed consent was obtained from participants at enrollment. At sample collection, participants were ≥60 years of age and in good general health, having no other neurological, psychiatric, or major medical diagnoses that could contribute importantly to dementia. Clinical diagnosis was evaluated based on criteria from the National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) . Cognitive status was rated with the clinical dementia rating scale (CDR); a CDR of 0 (N = 242) indicated no dementia, CDR 0.5 (N = 63) indicated very mild dementia, and CDR 1 (N = 28) indicated mild dementia . Some of the CDR 0.5 study participants met the criteria for mild cognitive impairment (MCI) and some were more mildly impaired and were considered “pre-MCI” , . A subset of participants (N = 179) in this cohort had also undergone positron emission tomography (PET) imaging with Pittsburgh Compound-B (PIB) for assessment of in vivo amyloid burden . A mean cortical PIB binding potential value was obtained by averaging prefrontal cortex, precuneus, lateral temporal cortex, and gyrus rectus regions, as described previously , . Apolipoprotein E (APOE) genotype was determined by the WU-ADRC Genetics Core. Twenty-five to 30 mL of CSF was collected by lumbar puncture (LP) at 8 AM following overnight fasting. Samples were inverted to avoid gradient effects, centrifuged briefly (2,000g, 5 minutes, 4°C) to remove any cellular elements, and aliquoted into polypropylene tubes for freezing and storage at −80°C .
CSF Aβ42, total tau, and phospho-tau181 levels (henceforth referred to as ‘traditional’ biomarkers) were analyzed in duplicate by the WU-ADRC Biomarker Core by quantitative ELISA after a single freeze-thaw cycle according to the manufacturer's specifications (Innotest, Innogenetics, Ghent, Belgium).
CSF samples were also evaluated by Rules Based Medicine, Inc. (RBM) (Austin, TX) for levels of 190 analytes using the Human Discovery Multi-Analyte Profile (MAP) 1.0 panel and a Luminex 100 platform. This 190 analyte panel (from here on referred to as ‘RBM analytes’) was assembled by RBM to measure a range of cytokines, chemokines, growth factors, hormones, metabolic markers, and other proteins thought to be important in disease; a complete list of analytes is available at www.rulesbasedmedicine.com.
At RBM, the samples were thawed at room temperature (RT), vortexed, spun at 13,000g for 5 minutes for clarification, and 1.0 mL was removed into a master microtiter plate for MAP analysis. Using automated pipetting, an aliquot of each sample was introduced into one of the capture microsphere multiplexes of the Human DiscoveryMAP. The mixtures of sample and capture microspheres were thoroughly mixed and incubated at RT for 1 hour. Multiplexed cocktails of biotinylated reporter antibodies for each multiplex were then added robotically, and after thorough mixing, were incubated for an additional hour at RT. Multiplexes were developed using an excess of streptavidin-phycoerythrin solution which was thoroughly mixed into each multiplex and incubated for 1 hour at RT. The volume of each multiplexed reaction was reduced by vacuum filtration and then increased by dilution into matrix buffer for analysis. Analysis was performed in a Luminex 100 instrument and the resulting data stream was interpreted using proprietary data analysis software developed at RBM. For each multiplex, both calibrators and controls were included on each microtiter plate. Eight-point calibrators were run in the first and last column of each plate and 3-level quality controls were included in duplicate. Testing results were determined first for the high, medium and low controls for each multiplex to ensure proper assay performance. Unknown values for each of the analytes localized in a specific multiplex were determined using 4 and 5 parameter, weighted and non-weighted curve fitting algorithms included in the data analysis package.
Statistical analyses were performed in SAS 9.2 (SAS Institute Inc, Cary, NC) for univariate analyses, ROC/AUC calculations, and Cox proportional hazards models, and in R version 2.10.1 for predictive modeling [packages/versions: caret (4.65), earth (2.4-0), kernlab (0.9–9), klaR (0.6–3), MASS (7.3–7), mda (0.4–1), nnet (7.3–1), pamr (1.44.0), pls (2.1–0), randomForest (4.5–34), spls (2.1–0)] . Of the 190 RBM analytes, 65 had >10% of data missing or below the lower detection limit (LDL), and were therefore excluded from analysis, yielding 125 ‘measurable’ analytes. Data below the LDL were imputed to LDL/2, and data more than five standard deviations beyond the mean were imputed using a nearest neighbor algorithm. Of the 125 measurable analytes, 24 analytes had at least one value below the LDL, imputed to LDL/2. For those 24 analytes, the percentage of data imputed ranged from < 1% (3 or fewer values) to 9.5% (33 values). There were a total of 82 outliers from 48 participants, with outliers in a maximum of 10 analytes for one participant, and in 2 – 9 analytes for the remaining participants. The distributions of analytes were tested for normality by Box-Cox analysis and, when appropriate, log10 transformed to approximate a normal distribution. Correlations between RBM analytes, traditional AD biomarkers, and demographic variables were evaluated using the Spearman rho correlation coefficient (α = 0.05). Analysis of covariance (ANCOVA) using the General Linear Model (GLM) procedure in SAS was used to determine analytes that differed in concentration between AD and control groups while adjusting for the effects of age and gender. Bonferroni correction was used to adjust for multiple testing (128 RBM plus traditional analytes). For each analyte showing promise by univariate analysis, the area under the Receiver Operating Characteristic (ROC) curve (AUC) was calculated for discriminating CDR 0 versus CDR>0. The method of Xiong et al.  was implemented to determine the optimum linear combination of analytes and to calculate the confidence interval (CI) on the AUC and the sensitivity. A bootstrapping resampling technique was used to obtain robust estimates of expected future performance of the three marker panels in predicting CDR 0 versus CDR>0. Averages of performance measures (the 95% CI of the AUC, sensitivity at 80% specificity, and p-value) were taken over 100 iterations of the bootstrap.
Cox proportional hazard models assessed the ability of baseline biomarkers to predict conversion from cognitive normalcy (CDR 0) to very mild or mild dementia (CDR 0.5 and 1). Data from participants who did not convert during the follow-up were statistically censored at the date of last assessment. Biomarker measurements were treated as continuous variables and were converted to standard Z-scores. Baseline variables were considered for inclusion in multivariate models if they were associated with time to conversion in a univariate analysis (p<0.15). Variables were retained in multivariate proportional hazard models if p<0.05. AIC (Akaike Information Criterion), a measure of goodness of fit of an estimated statistical model, was used to compare different models, with a lower AIC indicating better model fit.
Several statistical machine learning techniques were utilized to predict CDR status as a function of baseline characteristics (e.g. age) and the candidate biomarkers. Rather than focusing on a specific model, a panel of predictive modeling techniques was applied to the data. Most of these models contain “tuning parameters” that cannot be directly estimated from the data; these values were chosen using resampling techniques. The models used were:
- Partial Least Squares (PLS) is a latent variable model that produces linear class boundaries and works well with correlated predictors . Candidate values of the tuning parameter, the number of PLS components, ranged from 1 to 20.
- Sparse Partial Least Squares (SPLS) is a variant of PLS that incorporates feature selection in the model fitting . The number of PLS components was varied in the same manner as the basic PLS model and the additional tuning parameter for regularization was varied from 0.1 to 0.9.
- Random Forests (RF) is a tree-based ensemble method . The number of randomly selected variables at each split was varied over five values (generally 2 to the number of predictors in the model).
- Boosted Trees are another tree-based ensemble model . The three tuning parameters are the depth of the tree (even values from 2 to 10 were evaluated), the number of boosting iterations (20 iterations to 2000 in 100 iteration increments) and the learning rate (fixed at 0.1).
- Support Vector Machine (SVM) are a kernel based method . The radial basis function kernel was used. The kernel parameter was estimated analytically  and the five candidate values of the cost parameter ranged from 0.1 to 1,000 on the log10 scale.
- Nearest Shrunken Centroids (NCS) is a prototype model that incorporates feature selection . The tuning parameter, the shrinkage threshold, was varied over 30 values (between 0.325 and 9.097 for the model using traditional biomarkers, and between 0.325 and 9.11 for the model using traditional and RBM markers.)
- Naïve Bayes (NB) is a simple classifier where each predictor variable contributes to the final class prediction independently . The conditional distributions were computed using a simple Gaussian distribution or using a nonparametric density estimator.
- K-Nearest Neighbors (KNN) is a simple prototype based model . Candidate values for the number of neighbors ranged from 5 to 15.
- Flexible Discriminant Analysis (FDA) is a partitioning based model that also incorporates feature selection . The multivariate adaptive spline basis function was used. Ten candidate values for the number of retained terms were evaluated.
To determine the values for the tuning parameters and to estimate performance, resampling methods were used. The entire data set was repeatedly split into training (80%) and test sets (20%). This process was repeated 200 times. Models were fit on the training sets and the associated held-out values were used to estimate performance (sensitivity, specificity, and the area under the ROC curve). The final estimates of performance were calculated by averaging the 200 sets of performance values from the resampling procedure.
Levels of 37 markers are altered in MCI/very mild and mild AD CSF
To identify new candidate biomarkers for AD, multiplexed Luminex-based immunoassays were used to evaluate the levels of 190 analytes in the CSF of 242 cognitively normal participants (CDR 0), 63 participants with very mild dementia (CDR 0.5), and 28 participants with mild dementia (CDR 1) (participant characteristics at baseline assessment in Table 1). Since the number of CDR 1 participants was relatively smaller, and all CDR 0.5 and CDR 1 participants were clinically diagnosed as having AD, the CDR 0.5 and CDR 1 groups were combined in the statistical analyses. There were no statistically significant differences in age, gender, MCBP for PIB-PET, or APOE genotype between the CDR 0.5 and CDR 1 groups. Of the 125 RBM analytes that were statistically assessed (Table S1), the mean concentrations of 37 CSF analytes were found to differ between cognitively normal (CDR 0) and very mildly/mildly demented (CDR 0.5 and 1) participants by analysis of covariance (ANCOVA) adjusting for age and gender (p<0.05) (Table 2 and Table S2). Twelve of these 37 analytes remained significant after Bonferroni correction for multiple testing (n = 128, adjusted alpha = 0.0004). Additionally, participants with very mild/mild dementia exhibited the typical AD CSF biomarker profile characterized by significantly lower mean levels of CSF Aβ42 and higher mean levels of CSF tau and CSF p-tau181, as well as displaying higher mean cortical amyloid burden (MCBP assessed by PIB-PET imaging) as has been seen previously (Tables 1 and 2) , , .
Correlation of RBM analytes with demographic features and other biomarker values
Because the CDR 0, 0.5, and 1 groups showed somewhat different distributions with regard to age at lumbar puncture and gender, levels of the 37 RBM analytes were evaluated for correlation with these variables. Many analytes were significantly associated with age or gender (Table 3). Additionally, seeking insight into the potential roles of the analytes in AD pathology, we evaluated their association with CSF Aβ42, tau, and p-tau181, and cortical amyloid burden measured by PIB-PET imaging. Many of the analytes correlated with CSF tau and CSF p-tau181 (31 and 30 analytes, respectively), while fewer correlated with CSF Aβ42 or cortical amyloid burden (8 and 5 analytes, respectively) (Table 3).
Diagnostic Utility of Candidate Biomarkers
To assess the potential of the analytes for identifying very mild/mild dementia (combined CDR 0.5 and CDR 1), ROC curves and AUCs were calculated for each of the 37 RBM analytes and for traditional AD biomarkers Aβ42, tau, p-tau181 and the ratios tau/Aβ42 and p-tau181/Aβ42 (Table 4 and Figure 1). Although none of the RBM analytes alone out-performed the traditional biomarkers, combining traditional biomarkers with RBM analytes improved upon the AUC of the traditional biomarkers in many cases; e.g., Aβ42: AUC = .7552, combinations ranging from .7553–.8201; tau/Aβ42: AUC = .8443, combinations ranging from .8444–.8819; p-tau181/Aβ42: AUC = .8065, combinations ranging from .8065–.8468 (Table 4 and Figure 1). For these ‘2-marker panels’ of traditional biomarker plus RBM analyte, combinations with tau/Aβ42 consistently yielded the highest AUCs. To investigate whether combinations of three markers could yield a small panel with improved diagnostic accuracy, we utilized a targeted approach in which the four 2-marker panels with the highest AUCs (tau/Aβ42 + cystatin C, tau/Aβ42 + VEGF, tau/Aβ42 + KIM-1, tau/Aβ42 + PP) were combined with the 10 RBM analytes with the highest individual AUCs (indicated in Table 4). Because an independent validation cohort was not available for analysis, bootstrapping resampling with 100 iterations was performed to obtain relatively unbiased estimates of expected future performance of the ‘3-marker panels’ in predicting CDR 0 versus CDR>0 (Table 5). A number of the 3-marker panels demonstrated significantly improved AUCs compared to the corresponding 2-marker panels, with the best achieving AUCs of ~.90 and sensitivities of ~84% at 80% specificity (Table 5).
ROC analyses assessed the ability of the traditional biomarkers (blue) and of the 37 RBM analytes with p<0.05 in the univariate analyses (red) to discriminate CDR>0 from CDR 0 individuals. Combining the best-performing of the traditional biomarkers, the tau/Aβ42 ratio, with RBM analytes improved upon the AUC of tau/Aβ42 in many cases (green).
Because AD is a complex, multifactorial disease and likely involves alterations in multiple biological pathways, it is possible that a larger panel of biomarkers encompassing various features of AD pathophysiology may be optimal for disease diagnosis. Thus, we utilized statistical machine learning algorithms, which are more amenable to potentially large numbers of analyte combinations and can identify highly complex nonlinear relationships, to discover whether groups of markers are capable of distinguishing very mildly/mildly demented (CDR 0.5 and 1 combined) from cognitively normal participants (CDR 0). A multi-pronged analytical approach including RF, PLS, SPLS, Boosted Tree, FDA, NB, NSC, LR, KNN, and SVM was used, as each approach has its own strengths and weaknesses. Models were fit with two sets of predictors: 1) traditional biomarkers, and 2) traditional biomarkers plus RBM analytes; additionally, age, gender, and ApoE genotype were included in all models. Model performance measures were based on cross-validation, in which the test set results were averaged from 200 splits of the data between training (80%) and test (20%) (Table 6). Using either traditional biomarkers or traditional biomarkers with RBM analytes, no model clearly out-performed the others; however, the RBM analytes appeared to contribute additional specificity to the biomarker panels (traditional: sensitivity 80.6–91.4%, specificity 42.4–56.6%; traditional+ RBM: sensitivity 79.1–93.2%, specificity 59.6–77.6%). This improvement is further reflected in the Youden Index, a single statistic that captures the performance of a diagnostic test and is a function of sensitivity and specificity, which was higher on average for the models fitted with traditional plus RBM analytes (traditional: 0.230–0.438; traditional+RBM: 0.401–0.621). Additionally, models fitted with traditional plus RBM analytes yielded mostly higher AUCs (traditional: 0.680–0.827; traditional+RBM: 0.754–0.868). For the four models with a built-in importance statistic (i.e., Boosted Tree, NSC, RF, and PLS) there was considerable overlap in the top 15 predictors for each model (Figure 2, Table 7). Importantly, nearly all of the markers found to best discriminate CDR 0 from CDR>0 participants in the more targeted ROC analyses (Table 5) were also identified as the top predictors in the machine learning models (Figure 2, Table 7), reconfirming the potential of these analytes as biomarkers for AD.
For the four models with a built-in importance statistic (i.e., Boosted Tree, Nearest Shrunken Centroids, Random Forests, and Partial Least Squares), there is considerable overlap in the top 15 predictors for each model. Additionally, nearly all of the markers found to best discriminate CDR 0 from CDR>0 participants in the more targeted ROC analyses (Table 5), as shown here (‘Targeted’), were also identified as the top predictors in the machine learning models.
Prognostic Utility of Candidate Biomarkers
Identifying individuals with AD neuropathology while they are still in the preclinical phase will be critically important, as disease-modifying therapies currently in development are likely to be most effective early in the disease process before significant synaptic and neuronal loss has occurred. Thus, we used univariate and multivariate Cox proportional hazards models to evaluate the ability of the analytes to predict risk of developing cognitive impairment (conversion from CDR 0 to CDR>0). Of the 215 CDR 0 subjects with at least one follow-up annual clinical assessment, 29 received a CDR>0 at follow-up, and thus were classified as “converters.” Analyte measurements were converted to standard Z-scores to allow for comparison of hazard ratios between the different analytes. Variables with p<0.15 in the univariate Cox analyses were considered for inclusion in the multivariate model; variables were retained in the final model if p<0.05. By univariate Cox analysis, calbindin (p = 0.0163), cortisol (p = 0.0688), HGF (p = 0.1364), MCP-2 (p = 0.0412), MIG (p = 0.0208), MIF (p = 0.0950), S100B (p = 0.1275), TNF RII (p = 0.0645), TRAIL-R3 (p = 0.0833), Aβ42 (p = <0.0001), tau (p = 0.0071), and p-tau181 (p = 0.0087) were selected for further investigation by multivariate analysis. The final multivariate model consisted of calbindin (HR = 1.750, p = 0.0063), 1/Aβ42 (HR = 2.454, p<0.0001), and age at LP (HR = 1.096, p = 0.0002), with an overall HR of 4.704 (Table 8). Although calbindin and tau both had p<0.05 in the univariate analysis, the significant correlation between the two (r = 0.476, p<0.0001) prohibited inclusion of both variables in the multivariate model. Therefore, a second multivariate model consisted of tau (HR = 1.467, p = 0.0262), 1/Aβ42 (HR = 2.247, p<0.0001), and age at LP (HR = 1.098, p = 0.0003), with an overall HR of 3.619 (Table 8). However, the higher HR of calbindin than of tau, and the higher overall HR and lower AIC of the first model support it as the better model.
Biomarkers that can detect AD in its early stages and, importantly, predict future dementia will be invaluable for efficient clinical trial design and eventually patient care. This study identifies novel biomarkers that improve upon the ability of the best identified biomarkers to date to discriminate very mildly demented from cognitively normal participants, and identifies a novel biomarker with significant prognostic potential.
Using Luminex technology and a targeted multiplex panel, we identified 37 analytes (12 with Bonferroni correction) that are increased or decreased in the CSF of participants with early AD relative to cognitively normal controls. ROC analysis revealed that small combinations of a subset of these markers (cystatin C, VEGF, TRAIL-R3, PAI-1, PP, NT-proBNP, MMP-10, MIF, GRO-α, fibrinogen, FAS, and eotaxin-3) can enhance the ability of the best-performing of the traditional biomarkers, the tau/Aβ42 ratio, to discriminate CDR 0.5 and 1 from CDR 0 participants. Using alternative statistical strategies that are more amenable to the analysis of larger combinations of markers, multiple machine learning algorithms likewise showed that the novel biomarkers improved upon the diagnostic performance of the traditional biomarkers (Aβ42, tau, p-tau181). Importantly, nearly all of the markers found to best discriminate CDR 0 from CDR 0.5 and 1 participants in the more targeted ROC analyses were also identified as the top predictors in the machine learning models that contain a built-in importance statistic (10 of 12 markers). Thus, the potential of these analytes as biomarkers for AD is supported by alternative statistical approaches that yielded similar results. Further supporting these results is a recent report of the application of a smaller RBM Discovery MAP panel to a smaller cohort of AD, MCI, and control subjects ; this study identified a number of the same analytes as being differentially expressed in AD CSF as compared to control CSF and, although using different analytical approaches, included VEGF, TRAIL-R3, and eotaxin-3, in ‘combined’ models of novel and traditional biomarkers.
It is important to note that while the models used in our study suggest diagnostic value of the novel biomarkers, other combinations of these markers may be optimal; it will be of interest in future studies to validate the results of this discovery study in additional cohorts and to determine whether alternative combinations of these markers may demonstrate improved performance. The levels of at least 7 of the novel biomarkers have been evaluated in AD subjects in other studies: no change was observed in plasma PAI-1 levels ; in agreement with our findings, two studies have reported increased CSF MIF in AD and MCI subjects , ; also consistent with our findings, increased fibrinogen levels have been observed in AD and MCI CSF  and in AD plasma , and increased plasma levels have been associated with an increased risk of future dementia ; results have been mixed regarding CSF FAS levels in AD , ; AD plasma/serum VEGF levels have been reported to be unchanged , , decreased , and increased , while CSF levels have been reported to be unchanged  or increased ; no change in CSF or serum levels of TNF RII in AD has been reported ; cystatin C findings have been inconsistent, with reports of serum/plasma levels unchanged , increased in AD  or in those who later develop AD , and decreased  or decreased levels associated with increased risk of future AD , while CSF levels have been reported to be unchanged , , decreased , or increased . These inconsistent results may be due in part to the existence of a truncated form of cystatin C, which was found to be increased in AD CSF, while the full length protein was decreased , .
Furthermore, the potential involvement of each marker in AD pathophysiology necessitates investigation. The candidate biomarkers identified in the ROC and machine learning portions of this study belong to a wide variety of functional classes and pathways, including tissue remodeling and angiogenesis (MMP-10, VEGF), regulation of apoptosis (TRAIL-R3, FAS), neutrophil, eosinophil, and/or basophil chemotaxis (GRO-α, eotaxin-3), blood coagulation (Fibrinogen, PAI-1), intravascular volume homeostasis (NT-proBNP), and gastrointestinal and pancreatic secretions (PP). In addition, a number of molecules involved in inflammatory pathways were identified in the machine learning models (IL-7, IL-17E, TNF RII, MCP-2, FASL, MIF). The association of several of the candidate biomarkers with AD pathophysiology has already been probed, most notably for cystatin C, which appears to play a role in preventing Aβ oligomerization and amyloidogenesis –, and to a lesser extent for PAI-1 –, MIF , , fibrinogen , , FAS and FASL –, VEGF –, and TNF RII –.
It will be important in future studies to assess each candidate biomarker's value in diagnosis in independent sample sets when combined with other existing biomarkers or imaging tools. The existing gold standard validated biomarkers include CSF tau, p-tau181, and amyloid imaging, which differ between control and AD populations and mark underlying AD pathology , , , . Additionally, to follow up on these biomarker candidates, their ability to discriminate AD from other causes of dementia needs to be examined; indeed, several of these markers have already shown promise for distinguishing AD from frontotemporal lobar degeneration (cystatin C , eotaxin-3 , and HGF ). Incorporation of such markers into a biomarker panel may improve diagnostic specificity. Beyond their clinical use, these markers may have great value in the design of and enrollment in trials of disease-modifying therapies. By enrolling only subjects with lower or higher values of a particular marker (or panels of markers) indicative of AD, and excluding potential subjects with intermediate or ‘overlap’ values, one might provide greater diagnostic certainty than is possible through clinical evaluation alone. This is especially relevant for the design and evaluation of primary prevention trials in cognitively normal cohorts. Enriching study populations for subjects displaying certain biomarker levels may result in studies of greater efficacy, translating to reduced cost and duration.
This study also suggests a novel biomarker, CSF calbindin, that can predict risk of future dementia in individuals who are still cognitively normal. Previous studies have shown that Aβ42, tau, YKL-40 (an astrocyte marker), and the ratios tau/Aβ42 and YKL-40/Aβ42 can predict subsequent cognitive decline in non-demented cohorts , , . Using multivariate Cox proportional hazards models to determine the best combination of biomarkers for prognosis, we show here that a panel of markers consisting of calbindin, Aβ42, and age has predictive value comparable to, if not better than, a second panel consisting of tau, Aβ42, and age. Tissue culture studies have shown that increased expression of calbindin, a calcium binding protein present in central and peripheral nervous system neurons, correlates with increased resistance to cell death triggered by a variety of causes, including exposure to excitatory amino acids, ischemic injury, and Aβ –. Decreases in calbindin protein and mRNA levels  and number of calbindin-immunopositive neurons – have been observed in AD brains compared to controls. Further suggesting there may be a role for calbindin in AD pathophysiology is the large body of literature demonstrating that increased oxidative stress and altered calcium homeostasis appear to be interrelated mechanisms in AD pathogenesis. Interestingly, although not quite reaching statistical significance, we found that CSF calbindin levels trended higher in the very mildly/mildly demented group (p = .0660; CDR 0 = 145.9 ng/mL, CDR>0 = 157.4 ng/mL), suggesting that perhaps degenerating neurons release calbindin into the CSF. The immunohistochemical findings of a small study of 6 AD brains suggesting that calbindin-immunopositive neurons are relatively preserved in cases with moderate amyloid plaque and neurofibrillary content but are lost in more severe cases  prompts the question of whether CSF calbindin levels would be more significantly elevated in more severely demented individuals. Further studies are needed to confirm the prognostic potential of CSF calbindin, to determine if other complementary fluid or imaging biomarkers may improve upon its performance, and to more definitively elucidate its role in AD pathophysiology. As with the candidate diagnostic biomarkers, CSF calbindin may have value for clinical trial design by allowing for the selective enrollment of individuals who are at greater risk of developing cognitive impairment, resulting in clinical trials of shorter duration and reduced cost.
Means and standard deviations of the 125 RBM analytes and traditional biomarkers. The means and standard deviations of the 125 measurable RBM analytes and the traditional biomarkers are provided.
ANCOVA: Age and gender interactions. As shown in Table 2, the mean concentrations of 37 CSF RBM analytes were found to differ between cognitively normal (CDR 0) and very mildly/mildly demented (CDR 0.5 and 1) participants by analysis of covariance (ANCOVA) adjusting for age and gender (p<0.05). ANCOVA showed that a number of these analytes demonstrated significant interactions with age or gender, as shown here.
We gratefully acknowledge the contributions of the volunteer participants, lumbar puncture physicians, and the Clinical, Psychometrics, Biomarker, Imaging and Biostatistics Cores of the Knight Alzheimer's Disease Research Center at Washington University.
Conceived and designed the experiments: RC-S MK CX EHP TPM RJP KRB HS AMF DMH. Performed the experiments: RC-S MK CX TPM. Analyzed the data: RC-S MK CX EHP JL KRB HS DMH. Contributed reagents/materials/analysis tools: RC-S MK CX EHP TPM AMF DMH. Wrote the paper: RC-S MK TPM RJP HS DMH.
- 1. Craig-Schapiro R, Fagan AM, Holtzman DM (2009) Biomarkers of Alzheimer's disease. Neurobiol Dis 35: 128–140.
- 2. Hampel H, Burger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K (2008) Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement 4: 38–48.
- 3. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119–128.
- 4. Perrin RJ, Fagan AM, Holtzman DM (2009) Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461: 916–922.
- 5. Blennow K, Hampel H (2003) CSF Markers for Incipient Alzheimer's Disease. Lancet Neurol 2: 605–613.
- 6. Fagan A, Mintun M, Mach R, Lee S-Y, Dence C, Shah A, et al. (2006) Inverse relation between in vivo amyloid imaging load and CSF Aβ42 in humans. Ann Neurol 59: 512–519.
- 7. Fagan A, Roe C, Xiong C, Mintun M, Morris J, Holtzman D (2007) Cerebrospinal fluid tau/Aβ42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64: 343–349.
- 8. Fagan AM, Mintun MA, Shah AR, Aldea P, Roe CM, Mach RH, et al. (2009) Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med 1: 371–380.
- 9. Jagust WJ, Landau SM, Shaw LM, Trojanowski JQ, Koeppe RA, Reiman EM, et al. (2009) Relationships between biomarkers in aging and dementia. Neurology 73: 1193–1199.
- 10. Andreasen N, Hess C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. (1999) Cerebrospinal fluid β-amyloid(1-42) in Alzheimer's disease: Differences between early- and late-onset Alzheimer's disease and stability during the course of disease. Arch Neurol 56: 673–680.
- 11. Zetterberg H, Pedersen M, Lind K, Svensson M, Rolstad S, Eckerstrom C, et al. (2007) Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. J Alzheimers Dis 12: 255–260.
- 12. Andersson C, Blennow K, Almkvist O, Andreasen N, Engfeldt P, Johansson SE, et al. (2008) Increasing CSF phospho-tau levels during cognitive decline and progression to dementia. Neurobiol Aging 29: 1466–1473.
- 13. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, et al. (2009) Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. PLoS One 4: e6294.
- 14. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association Between CSF Biomarkers and Incipient Alzheimer's Disease in Patients with Mild Cognitive Impairment: A Follow-Up Study. Lancent Neurology 5: 228–234.
- 15. Li G, Sokal I, Quinn J, Leverenz J, Brodey M, Schellenberg G, et al. (2007) CSF tau/Aβ42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology 69: 631–639.
- 16. Sunderland T, Linker G, Mirza N, Putnam K, Friedman D, Kimmel L, et al. (2003) Decreased β-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 289: 2094–2103.
- 17. Zhang J, Goodlett DR, Quinn JF, Peskind E, Kaye JA, Zhou Y, et al. (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7: 125–133; discussion 173-180.
- 18. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. (2010) Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta Neuropathol 119: 669–678.
- 19. Simonsen A, McGuire J, Hansson O, Zetterberg H, Podust V, Davies H, et al. (2007) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64: 366–370.
- 20. Simonsen AH, McGuire J, Podust VN, Hagnelius NO, Nilsson TK, Kapaki E, et al. (2007) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia. Dement Geriatr Cogn Disord 24: 434–440.
- 21. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, et al. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3: 1486–1494.
- 22. Davidsson P, Westman-Brinkmalm A, Nilsson C, Lindbjer M, Paulson L, Andreasen N, et al. (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. NeuroReport 13: 611–615.
- 23. Abdi F, Quinn J, Jankovic J, McIntosh M, Leverenz J, Peskind E, et al. (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9: 293–348.
- 24. Finehout EJ, Franck Z, Choe LH, Relkin N, Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann Neurol 61: 120–129.
- 25. Puchades M, Folkesson Hansson S, Nilsson C, Andreasen N, Blennow K, Davidsson P (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Mol Brain Res 118: 140–146.
- 26. Hu Y, Hosseini A, Kauwe J, Gross J, Cairns N, Goate A, et al. (2007) Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease. Proteomics - Clin Appl 1: 1373–1384.
- 27. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939–944.
- 28. Morris JC (1993) The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology 43: 2412–2414.
- 29. Storandt M, Grant E, Miller J, Morris J (2006) Longitudinal course and neuropathologic outcomes in original vs revised MCI and in pre-MCI. Neurology 67: 467–473.
- 30. Petersen R, Smith G, Waring S, Ivnik R, Tabgalos E, Kokmen E (1999) Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol 56: 303–308.
- 31. Mintun M, LaRossa G, Sheline Y, Dence C, Lee S-Y, Mach R, et al. (2006) [11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67: 446–452.
- 32. Klunk W, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt D, et al. (2004) Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55: 306–319.
- 33. Team RDC (2010) R: A language and environment for statistical computing. R Foundation for Statistical Computing.
- 34. Xiong C, McKeel D, Miller J, Morris J (2004) Combining correlated diagnostic tests---application to neuropathologic diagnosis of Alzheimer's disease. Medical Decision Making 24: 659–669.
- 35. Gerlach RW, Kowalski BR, Wold HOA (1979) Partial least-squares path modelling with latent variables. Analytica Chimica Acta 112: 417–421.
- 36. Chun H, Keleş SSparse partial least squares regression for simultaneous dimension reduction and variable selection. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 72: 3–25.
- 37. Breiman L (2001) Random Forests. Mach Learn 45: 5–32.
- 38. Friedman JH (2001) Greedy Function Approximation: A Gradient Boosting Machine. The Annals of Statistics 29: 1189–1232.
- 39. Boser BE, Guyon IM, Vapnik VN (1992) A training algorithm for optimal margin classifiers. Proceedings of the fifth annual workshop on Computational learning theory. Pittsburgh, Pennsylvania, United States: ACM.
- 40. Caputo B, Sim K, Furesjo F, Smola A (2001) Appearance-based object recognition using SVMs: which kernel should I use? Proceedings of Neural Information Processing Systems Workshop on Statistical methods for Computational Experiments In Visual Processing and Computer Vision. Whistler.
- 41. Tibshirani R, Hastie T, Narasimhan B, Chu G (2003) Class Prediction by Nearest Shrunken Centroids, with Applications to DNA Microarrays. Statistical Science 18: 104–117.
- 42. Hastie T, Tibshirani R, Friedman JH (2001) The Elements of Statistical Learning. New York: Springer-Verlag.
- 43. Hastie T, Tibshirani R, Buja A (1993) Flexible Discriminant Analysis by Optimal Scoring. Journal of the American Statistical Association 89: 1255–1270.
- 44. Ban Y, Watanabe T, Suguro T, Matsuyama TA, Iso Y, Sakai T, et al. (2009) Increased plasma urotensin-II and carotid atherosclerosis are associated with vascular dementia. J Atheroscler Thromb 16: 179–187.
- 45. Bacher M, Deuster O, Aljabari B, Egensperger R, Neff F, Jessen F, et al. (2010) The role of macrophage migration inhibitory factor in Alzheimer's disease. Mol Med 16: 116–121.
- 46. Popp J, Bacher M, Kolsch H, Noelker C, Deuster O, Dodel R, et al. (2009) Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 43: 749–753.
- 47. Lee JW, Namkoong H, Kim HK, Kim S, Hwang DW, Na HR, et al. (2007) Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease. BMC Neurol 7: 14.
- 48. Chang CY, Liang HJ, Chow SY, Chen SM, Liu DZ (2007) Hemorheological mechanisms in Alzheimer's disease. Microcirculation 14: 627–634.
- 49. van Oijen M, Witteman JC, Hofman A, Koudstaal PJ, Breteler MM (2005) Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36: 2637–2641.
- 50. Tarkowski E, Wallin A, Regland B, Blennow K, Tarkowski A (2001) Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand 103: 166–174.
- 51. Martinez M, Fernandez-Vivancos E, Frank A, De la Fuente M, Hernanz A (2000) Increased cerebrospinal fluid fas (Apo-1) levels in Alzheimer's disease. Relationship with IL-6 concentrations. Brain Res 869: 216–219.
- 52. Leyhe T, Hoffmann N, Stransky E, Laske C (2009) Increase of SCF plasma concentration during donepezil treatment of patients with early Alzheimer's disease. Int J Neuropsychopharmacol 12: 1319–1326.
- 53. Del Bo R, Scarlato M, Ghezzi S, Martinelli Boneschi F, Fenoglio C, Galbiati S, et al. (2005) Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 57: 373–380.
- 54. Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Fernandez-Viadero C, Pena N, et al. (2007) Low serum VEGF levels are associated with Alzheimer's disease. Acta Neurol Scand 116: 56–58.
- 55. Chiappelli M, Borroni B, Archetti S, Calabrese E, Corsi MM, Franceschi M, et al. (2006) VEGF gene and phenotype relation with Alzheimer's disease and mild cognitive impairment. Rejuvenation Res 9: 485–493.
- 56. Blasko I, Lederer W, Oberbauer H, Walch T, Kemmler G, Hinterhuber H, et al. (2006) Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement Geriatr Cogn Disord 21: 9–15.
- 57. Tarkowski E, Issa R, Sjogren M, Wallin A, Blennow K, Tarkowski A, et al. (2002) Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia. Neurobiol Aging 23: 237–243.
- 58. Lanzrein AS, Johnston CM, Perry VH, Jobst KA, King EM, Smith AD (1998) Longitudinal study of inflammatory factors in serum, cerebrospinal fluid, and brain tissue in Alzheimer disease: interleukin-1beta, interleukin-6, interleukin-1 receptor antagonist, tumor necrosis factor-alpha, the soluble tumor necrosis factor receptors I and II, and alpha1-antichymotrypsin. Alzheimer Dis Assoc Disord 12: 215–227.
- 59. Kalman J, Marki-Zay J, Juhasz A, Santha A, Dux L, Janka Z (2000) Serum and cerebrospinal fluid cystatin C levels in vascular and Alzheimer's dementia. Acta Neurol Scand 101: 279–282.
- 60. Straface E, Matarrese P, Gambardella L, Vona R, Sgadari A, Silveri MC, et al. (2005) Oxidative imbalance and cathepsin D changes as peripheral blood biomarkers of Alzheimer disease: a pilot study. FEBS Lett 579: 2759–2766.
- 61. Lopez OL, Kuller LH, Mehta PD, Becker JT, Gach HM, Sweet RA, et al. (2008) Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70: 1664–1671.
- 62. Chuo LJ, Sheu WH, Pai MC, Kuo YM (2007) Genotype and plasma concentration of cystatin C in patients with late-onset Alzheimer disease. Dement Geriatr Cogn Disord 23: 251–257.
- 63. Sundelof J, Arnlov J, Ingelsson E, Sundstrom J, Basu S, Zethelius B, et al. (2008) Serum cystatin C and the risk of Alzheimer disease in elderly men. Neurology 71: 1072–1079.
- 64. Brettschneider J, Riepe MW, Petereit HF, Ludolph AC, Tumani H (2004) Meningeal derived cerebrospinal fluid proteins in different forms of dementia: is a meningopathy involved in normal pressure hydrocephalus? J Neurol Neurosurg Psychiatry 75: 1614–1616.
- 65. Hansson SF, Andreasson U, Wall M, Skoog I, Andreasen N, Wallin A, et al. (2009) Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer's disease patients. J Alzheimers Dis 16: 389–397.
- 66. Kaeser SA, Herzig MC, Coomaraswamy J, Kilger E, Selenica ML, Winkler DT, et al. (2007) Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 39: 1437–1439.
- 67. Selenica ML, Wang X, Ostergaard-Pedersen L, Westlind-Danielsson A, Grubb A (2007) Cystatin C reduces the in vitro formation of soluble Abeta1-42 oligomers and protofibrils. Scand J Clin Lab Invest 67: 179–190.
- 68. Sastre M, Calero M, Pawlik M, Mathews PM, Kumar A, Danilov V, et al. (2004) Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging 25: 1033–1043.
- 69. Tizon B, Ribe EM, Mi W, Troy CM, Levy E (2010) Cystatin C protects neuronal cells from amyloid-beta-induced toxicity. J Alzheimers Dis 19: 885–894.
- 70. Mi W, Pawlik M, Sastre M, Jung SS, Radvinsky DS, Klein AM, et al. (2007) Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet 39: 1440–1442.
- 71. Fabbro S, Seeds NW (2009) Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. Journal of Neurochemistry 109: 303–315.
- 72. Melchor JP, Pawlak R, Strickland S (2003) The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 23: 8867–8871.
- 73. Cacquevel M, Launay S, Castel H, Benchenane K, Cheenne S, Buee L, et al. (2007) Ageing and amyloid-beta peptide deposition contribute to an impaired brain tissue plasminogen activator activity by different mechanisms. Neurobiol Dis 27: 164–173.
- 74. Oyama R, Yamamoto H, Titani K (2000) Glutamine synthetase, hemoglobin alpha-chain, and macrophage migration inhibitory factor binding to amyloid beta-protein: their identification in rat brain by a novel affinity chromatography and in Alzheimer's disease brain by immunoprecipitation. Biochim Biophys Acta 1479: 91–102.
- 75. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, et al. (2010) Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron 66: 695–709.
- 76. Paul J, Strickland S, Melchor JP (2007) Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 204: 1999–2008.
- 77. Su JH, Anderson AJ, Cribbs DH, Tu C, Tong L, Kesslack P, et al. (2003) Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiol Dis 12: 182–193.
- 78. Erten-Lyons D, Jacobson A, Kramer P, Grupe A, Kaye J (2010) The FAS gene, brain volume, and disease progression in Alzheimer's disease. Alzheimers Dement 6: 118–124.
- 79. Ethell DW, Kinloch R, Green DR (2002) Metalloproteinase shedding of Fas ligand regulates beta-amyloid neurotoxicity. Curr Biol 12: 1595–1600.
- 80. Morishima Y, Gotoh Y, Zieg J, Barrett T, Takano H, Flavell R, et al. (2001) Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci 21: 7551–7560.
- 81. Burger S, Noack M, Kirazov LP, Kirazov EP, Naydenov CL, Kouznetsova E, et al. (2009) Vascular endothelial growth factor (VEGF) affects processing of amyloid precursor protein and beta-amyloidogenesis in brain slice cultures derived from transgenic Tg2576 mouse brain. Int J Dev Neurosci 27: 517–523.
- 82. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, Comi GP (2009) VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. J Neurol Sci 283: 66–68.
- 83. Patel NS, Mathura VS, Bachmeier C, Beaulieu-Abdelahad D, Laporte V, Weeks O, et al. (2010) Alzheimer's beta-amyloid peptide blocks vascular endothelial growth factor mediated signaling via direct interaction with VEGFR-2. J Neurochem 112: 66–76.
- 84. Cheng X, Yang L, He P, Li R, Shen Y (2010) Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients. J Alzheimers Dis 19: 621–630.
- 85. Patel JR, Brewer GJ (2008) Age-related differences in NFkappaB translocation and Bcl-2/Bax ratio caused by TNFalpha and Abeta42 promote survival in middle-age neurons and death in old neurons. Exp Neurol 213: 93–100.
- 86. Zhao M, Cribbs DH, Anderson AJ, Cummings BJ, Su JH, Wasserman AJ, et al. (2003) The induction of the TNFalpha death domain signaling pathway in Alzheimer's disease brain. Neurochem Res 28: 307–318.
- 87. Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, et al. (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68: 903–912.
- 88. Guo Q, Christakos S, Robinson N, Mattson MP (1998) Calbindin D28k blocks the proapoptotic actions of mutant presenilin 1: reduced oxidative stress and preserved mitochondrial function. Proc Natl Acad Sci U S A 95: 3227–3232.
- 89. Goodman JH, Wasterlain CG, Massarweh WF, Dean E, Sollas AL, Sloviter RS (1993) Calbindin-D28k immunoreactivity and selective vulnerability to ischemia in the dentate gyrus of the developing rat. Brain Res 606: 309–314.
- 90. Mattson MP, Rychlik B, Chu C, Christakos S (1991) Evidence for calcium-reducing and excito-protective roles for the calcium-binding protein calbindin-D28k in cultured hippocampal neurons. Neuron 6: 41–51.
- 91. Prehn JH, Bindokas VP, Jordan J, Galindo MF, Ghadge GD, Roos RP, et al. (1996) Protective effect of transforming growth factor-beta 1 on beta-amyloid neurotoxicity in rat hippocampal neurons. Mol Pharmacol 49: 319–328.
- 92. Iacopino AM, Christakos S (1990) Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci U S A 87: 4078–4082.
- 93. Lechner T, Adlassnig C, Humpel C, Kaufmann WA, Maier H, Reinstadler-Kramer K, et al. (2004) Chromogranin peptides in Alzheimer's disease. Exp Gerontol 39: 101–113.
- 94. Iritani S, Niizato K, Emson PC (2001) Relationship of calbindin D28K-immunoreactive cells and neuropathological changes in the hippocampal formation of Alzheimer's disease. Neuropathology 21: 162–167.
- 95. Greene JR, Radenahmad N, Wilcock GK, Neal JW, Pearson RC (2001) Accumulation of calbindin in cortical pyramidal cells with ageing; a putative protective mechanism which fails in Alzheimer's disease. Neuropathol Appl Neurobiol 27: 339–342.